|Dr. Jonathan E. Lim||Co-Founder, Chairman & CEO||480k||N/A||1972|
|Dr. David M. Chacko M.D.||Chief Financial Officer||455.3k||N/A||1983|
|Dr. Michael D. Varney Ph.D.||Chairman of R&D, Scientific Advisory Board member and Director||26.3k||N/A||1958|
|Dr. Nik Chetwyn Ph.D.||Sr. VP of Operations||N/A||N/A||N/A|
|Mr. Ebun S. Garner J.D., Esq.||Gen. Counsel & Corp. Sec.||N/A||N/A||1972|
|Dr. Wei Lin M.D.||Chief Medical Officer||N/A||N/A||1969|
|Mr. Brian L. Baker CPA, M.S., MS, CPA||Sr. VP of Fin.||N/A||N/A||1967|
|Ms. Chandra D. Lovejoy||Sr. VP of Regulatory Affairs||N/A||N/A||1971|
|Dr. Robert Shoemaker Ph.D.||Sr. VP of Research||N/A||N/A||1981|
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of NSCLC, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. The company was incorporated in 2018 and is headquartered in San Diego, California.
Erasca, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.